SAMHD1 promotes chemoresistance because, given the structural similarity to endogenous dNTP, the nucleotide analogs used for acute myeloid leukemia and mantle cell lymphoma treatments are degraded by SAMHD113–15. This evidence concerns the gene SAMHD1 and mantle cell lymphoma.